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ABSTRACT 
Objective: Tissue accumulation of 18F-FDG is quantified as standardised uptake 
value (SUV), which may be expressed as the voxel maximum (SUVmax) or mean 
(SUVmean). SUVmax/SUVmean may be a marker of hepatic steatosis, while the 
coefficient of variation (CV) of SUV may be a marker of hepatic fat distribution 
heterogeneity (HFDH). Alternatively, they may reflect low signal-to-noise ratio 
(‘noise’) in obese persons in whom hepatic steatosis is common. The study aim was to 
compare the impact of body size on noise versus SUV and CT density (CTD). 
Methods: Dynamic PET was performed (30x1 min frames) following FDG injection 
in 60 patients undergoing routine PET/CT. Hepatic FDG clearance was measured 
using Patlak-Rutland graphical analysis with abdominal aorta as input. Noise was 
quantified as the standard deviation (SD) of the plot residuals (ignoring the first 2 
frames), normalised to the intercept (NRMSD). SUVmax, SUVmean and CTD were 
measured from 60 min whole body PET/CT. CV of SUV and SD of CTD were 
quantified in 28/60 patients using texture analysis. 
Results: NRMSD correlated with weight (r=0.49; p<0.0001) and BMI (r=0.48; 
p=0.0001). SUVmax, SUVmean, SUVmax/SUVmean, CV of SUV, CTD, and SD of CTD 
all correlated strongly with weight and BMI (p<0.0001). However, they correlated 
weakly with NRMSD, the strongest being SUVmax (r=0.34; p=0.008) and SD of CTD 
(r=0.42; n=28; p=0.026). 
Conclusions: Noise is increased in overweight/obese persons but has little effect on 
SUV indices, CTD and their variabilities. SUVmax/SUVmean and CV of SUV are 
therefore, to some extent, markers of hepatic steatosis and HFDH, respectively. 
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INTRODUCTION 
There have been several studies on the advantages and disadvantages of different 
ways of quantifying tissue 18F-FDG accumulation on PET/CT, including glucose 
utilization rate (MRglu) [1-3], FDG clearance [4-6] and standardized uptake value 
(SUV) [7-9]. The most widely used parameter is SUV, which is the tissue FDG 
concentration per unit of administered FDG. It is multiplied by a metric of whole 
body size, usually body weight, to account for the dilution of FDG throughout its 
whole body distribution volume. SUV can be expressed as the mean of voxel values 
in a region of interest (SUVave) or as the maximum voxel value (SUVmax).   
 
There has been recent interest in FDG accumulation in the liver. The liver is used as a 
reference region for the quantification of tumour FDG uptake, especially adrenal 
glands [10] and lymphoma [11] and the validity of the liver for this, especially when 
it is pathologically fatty, has been studied [12-15]. There is also interest in the use of 
FDG for studying glucose metabolism in hepatic steatosis [16] and for diagnosing 
hepatic inflammation, such as in steatohepatitis [15].  
 
SUV faces problems with respect to the liver as a result of spurious correlations 
arising from multiple inter-correlations that exist between hepatic steatosis, blood 
glucose level and body habitus because patients with hepatic steatosis tend to have 
high blood glucose and be obese [17,18]. Moreover, it has been suggested that SUV 
calculated using weight is overestimated in obese persons because comparatively little 
FDG enters adipose tissue and lean body mass (LBM) has been proposed as a better 
alternative [19,20]. Hepatic SUV also correlates with blood glucose in a rather 
complex non-linear fashion [21].  
 
Another concern is that signal-to-noise ratio may be reduced in obese persons. It is 
thought that SUVmax is particularly susceptible to noise because it is based on a single 
voxel, while SUVmean is less susceptible [9,22]. This implies that SUVmax/SUVmean, 
which has been proposed to be a marker of hepatic fat [17], would also be susceptible 
to noise.  The regional variability of SUV has been proposed as a possible marker of 
hepatic fat heterogeneity but again may also simply be determined by noise [23]. 
 
The aim of this study, therefore, was to examine the associations of CT density and 
SUV indices, and their regional variabilities, with signal-to-noise ratio in FDG 
PET/CT.  
 
METHODS  
Patients 
Sixty patients having routine clinically indicated FDG PET/CT for the management of 
cancer agreed to undergo dynamic imaging in addition to their routine clinical study. 
Patients with focal liver pathology identified on PET/CT were excluded. Body mass 
index (BMI) was calculated as weight/height2 and LBM from height, weight and 
gender using the equations of Boer [24].  
 
All patients gave informed consent for the dynamic study, which is not part of our 
routine scanning protocol, and for use of their routine 60 min data. The study was 
approved by a local institutional review board.  
 
 
 
 
 
Imaging 
Whole body imaging 
All patients had routine whole-body PET/CT 60 min post-injection of ~400 MBq 
FDG. Patients fasted for 6 h before FDG injection. Blood glucose was measured using 
a glucometer (ACCU-CHEK Performa; Inform ll strips; USA). 
 
A Siemens Biograph 64-slice PET scanner, with immediate non-enhanced CT 
scanning (120 Kvp/50 mA - Care dose 4D; slice 5 mm; pitch 0.8; rotational speed 
0.5/sec), was used to cover the area from the orbital margin to the lower trochanters. 
Arms were up, as arms down may result in artificial elevation of the liver FDG signal 
due to beam-hardening effects. 3D emission data were then acquired at 3 min per bed 
position (PET reconstruction: 4 iterations; subset 8; Gaussian pre-filter; FWHM 5 
mm; matrix size 168x168; zoom 1). 
 
Dynamic imaging 
In addition to their routine imaging, patients consented to additional dynamic imaging 
at one frame per min for 30 min starting immediately following FDG injection in a 
single bed position with detectors over the torso. CT was switched off so that there 
was no additional radiation dose over and above that indicated for the routine clinical 
study.    
 
Image analysis 
Whole body imaging 
SUVmax, SUVmean and CT density were measured from a 3 cm region of interest over 
the right lobe of the liver. In 28 of the 60 patients, texture analysis of the liver was 
performed on the routine 60 min PET and CT scans from large volumes of interest 
(ranging from 160 – 1300 voxels) using in-house software implemented under 
MATLAB (The MathWorks Inc.) for measurement of the coefficient of variation 
(CV) of SUV and the standard deviation (SD) of CTD.   
 
Dynamic imaging 
Images were analysed using HERMES software. Hepatic FDG clearance was 
measured using Patlak-Rutland graphical analysis [5,25]. Hepatic activity was 
summed from regions of interest (ROI) of 3.0 cm diameter over the right lobe on 
about 20 transaxial images. Blood pool activity was obtained similarly from ROIs of 
1.6 cm diameter on about 20 transaxial images of the abdominal aorta.  
 
The gradient of the Patlak-Rutland plot, which reflects the rate of FDG 
phosphorylation, is proportional to FDG clearance. The intercept is proportional to the 
distribution volume of FDG [4,25] with identical proportionality constants relating 
slope to clearance. The first 2 frame values, during which mixing of tracer between 
blood and hepatic tissue distribution volume was assumed to take place, were not 
included in the analysis.  
 
The correlation coefficient of the Patlak-Rutland plot (RP-R) was recorded. ‘Noise’ 
was quantified from the Patlak-Rutland plot as the standard deviation (SD) of the 
residuals of the points and calculated from the following equation. 
 
SD   =  ([residual2]/[28-1])0.5      (12.1) 
 
where the residual is the y value at any time, t, minus the regression line y value at the 
same time (Fig 1).  The SD was then normalised by dividing it by the intercept of the 
plot to give the ‘normalised root mean standard deviation’ (NRMSD) or ‘noise’. 
Examples of Patlak-Rutland plots with high noise and low noise are shown in Fig 1.   
 
RESULTS 
1. Correlations of NRMSD with whole body metrics, RP-R and administered 
activity 
Mean NRMSD was 0.081 (SD 0.032). NRMSD correlated with weight (r = 0.49; p < 
0.0001), BMI (r = 0.48; p = 0.0001) and LBM (r = 0.41; p = 0.001) (Table 1), 
suggesting that noise is increased in large persons. NRMSD showed no significant 
correlation with administered activity (r = -0.02) or RP-R (r = -0.08). Dividing weight 
by administered activity did not increase its correlation with NRMSD (r = 0.47).  RP-R 
did not correlate with weight (r = 0.14) or BMI (r = -0.07). 
 
2. Correlations of SUV indices and CT density with whole body size metrics 
SUVmax/SUVmean correlated with CT density (r = 0.42; n = 60; p = 0.008), suggesting 
that it is a measure of hepatic fat, as suggested previously [21]. The CV of SUV 
correlated with CT density (r = 0.46; n = 28; p = 0.014). It also correlated strongly 
with the SD of CT density (r = 0.75; p < 0.0001), suggesting that both these 
variabilities may be markers of hepatic fat distribution heterogeneity [23].  
SUVmax/SUVmean, CT density, CV of SUV and SD of CT density all correlated 
strongly with weight, BMI and LBM (Table 1). The correlations of SUVmax and 
SUVmean with weight were also both strong (r = 0.69 and 0.50 [p < 0.0001], 
respectively; Table 2), but this would be expected as both are calculated using weight. 
 3. Correlations of NRMSD with SUV indices and CT density 
In contrast to their correlations with whole body size metrics, SUVmax/SUVmean (r = 
0.24; p = 0.045), CT density (r = -0.24; p = 0.065), CV of SUV (r = 0.33; n = 28; p = 
0.086) and SD of CT density (r = 0.42; n = 28; p = 0.026) all showed weak or 
insignificant correlations with NRMSD (Table 2). SUVmax correlated more strongly 
with NRMSD (r = 0.34; p = 0.008) than SUVmean, which showed a weak correlation 
with NRMSD (r = 0.26; p = 0.045), consistent with the notion that SUVmax is more 
susceptible to noise than SUVmean.  
 
DISCUSSION 
Body habitus has a significant association with the signal-to-noise ratio expressed in 
terms of the scatter of data points around the regression line of the Patlak-Rutland 
suggesting that signal-to-noise ratio is decreased in large persons.  
 
There are several patient-related issues that could influence signal-to-noise ratio. The 
first is the administered activity of FDG. Surprisingly this did not correlate with 
NRMSD, perhaps because the range of administered activities was quite narrow.  The 
second is body size and more specifically the whole body volume throughout which 
FDG is distributed and diluted. There is evidence to suggest that the distribution space 
is closer to LBM than body weight [19]. Thirdly, the size of the individual determines 
the mean path length of photons from the aorta and liver to the detector. Thus, photon 
attenuation will be greater in large individuals. The distance in water over which 511 
keV photons lose 50% of counts by attenuation (‘half distance’, analogous to half life) 
is 7.3 cm. So increased abdominal girth could have a significant impact on the count 
density. Fourthly, patient movement would also decrease signal-to-noise ratio but 
would not be expected to correlate with body size indices so should play no role in 
determining the influence of body size on NRMSD.  
 
With regard to the interpretation of the correlations of NRMSD with SUV indices and 
CT density and their variabilities, a critical assumption in this study is that if there is 
increased noise in the dynamic study, there will also be increased noise in the static 
study. This is a reasonable assumption if the principal determinant of noise is body 
size and is supported by the finding of a significant correlation between SUVmax and 
NRMSD.  Thus, as it is based on a single voxel, SUVmax is thought to be more 
susceptible to noise than SUVmean. The correlation of noise with SUVmax, however, 
may be the result of the respective correlations of weight with SUV indices (which 
are calculated using weight) and NRMSD with weight, except a non-significant 
correlation was seen between SUVmean and NRMSD. 
 
Previous studies have shown that SUVmax/SUVmean correlates with CT density 
[21,23]. Presumably FDG does not enter hepatic fat so SUVmax will be based on a 
relatively fat-free voxel in contrast to SUVmean, which will be ‘diluted’ by hepatic fat. 
It was therefore suggested that the ratio is a measure of hepatic fat [21]. An 
alternative explanation for the correlation of SUVmax/SUVmean with CT density is low 
signal-to-noise ratio in patients with fatty liver who tend to be large. Accordingly, 
SUVmax/SUVmean correlated moderately strongly with weight. However, it correlated 
weakly with NRMSD. If the correlation of the ratio with weight was the result of 
patient-related noise, it would have been expected to correlate more strongly with 
NRMSD.  
 A previous study raised the possibility that the variabilities of SUVmax/SUVmean and 
CT density are markers of hepatic fat heterogeneity [23]. The close correlations 
between CV of SUV and SD of CT density and between both of these variabilities 
and body size metrics is consistent with this claim, although, as with 
SUVmax/SUVmean, these correlations may be the result of high body size. But again, as 
with SUVmax/SUVmean, if they were the result of patient-related noise, they would be 
expected to correlate more closely with NRMSD. The correlation between CV of 
SUV and mean CT density is therefore likely, at least partly, to be the result of 
hepatic fat heterogeneity in hepatic steatosis. 
 
The absence of correlation between NRMSD and RP-R can be explained by the fact 
that unlike RP-R, NRMSD is not influenced by the gradient of a regression. In contrast, 
RP-R tends to increase with regression slope gradient. For example, with a gradient of 
zero, the correlation coefficient will be zero. If all the residuals were all zero, then 
NRMSD would also be zero.  
 
In conclusion, we have used scatter in the Patlak-Rutland plot to assess signal-to-
noise ratio, which appears to be increased in heavy persons. The study supports the 
notion that SUVmax/SUVmean is a marker of hepatic fat. Although CV of SUV and SD 
of CT density are susceptible to noise, they are at least partly markers of hepatic fat 
distribution heterogeneity. Correcting them for the effects of noise would nevertheless 
be desirable if they were to be used as such markers. 
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Figure 1.  Examples of Patlak-Rutland plots showing high signal-to-noise ratio 
(upper panel, NRSMD = 0.125; RP-R = 0.63) and low signal-to-noise ratio (lower 
panel; NRSMD = 0.035; RP-R = 0.95).  Vertical lines illustrate residuals. 
 
  
TABLES 
Table 1. Correlation coefficients (p) of relationships of NRMSD, SUV indices and 
CT density with metrics of whole body size. 
 
    n          Weight      BMI    LBM 
____________________________________________________________________ 
NRMSD  60          0.49    0.48 (0.0001)        0.41 (0.001) 
SUVmean  60          0.50    0.59          0.27 (0.04) 
SUVmax  60          0.69    0.76          0.47 (0.0002) 
SUVmax/SUVmean 60          0.55    0.56          0.48 
CT density  60          0.52    0.40 (0.002)         0.49  
CV SUV  28          0.85    0.78           0.80  
SD CT density 28          0.67 (<0.0001)   0.71                      0.56 (0.002) 
____________________________________________________________________ 
 
 
 
 
Table 2. Correlation coefficients (p) of relationships of SUV indices and CT density 
with NRMSD 
 
 
     n    NRMSD   
___________________________________________________ 
SUVmean   60  0.26 (0.045) 
SUVmax   60  0.34 (0.008) 
SUVmax/SUVmean  60  0.24 (0.065)   
CT density   60  0.24 (0.065)    
CV of SUV   28  0.33 (0.086)    
SD of CT density  28  0.42 (0.026)   
____________________________________________________ 
 
